scholarly journals PROGNOSTIC MARKERS IN IMMUNOHISTOCHEMICAL DIAGNOSIS OF METASTASES OF COLORECTAL PHENOTYPE CARCINOMA OF UNKNOWN PRIMARY

2019 ◽  
Vol 19 (1) ◽  
pp. 77-83
Author(s):  
O.V. Poslavska
Keyword(s):  
Nuclear Translocation ◽  
Regulatory Protein ◽  
Unknown Primary ◽  
Colorectal Cancers ◽  
Ki 67 ◽  
Immunohistochemical Markers ◽  
Primary Colon ◽  
New Gene ◽  
Her 2 ◽  
Focal Expression

Most metastases of cancers of unknown primary (80% -85%) are known as having unfavourable prognostic variants due to their large extant and low susceptibility to the therapy. Studies of prognostic immunohistochemical markers will provide an opportunity to understand the biological features of the rapid dissemination of individual colorectal phenotypes. In recent decades, p53 and Ki-67, the most popular antibodies have been investigated as prognostic factors for colorectal cancer. The p53 protein is a regulatory protein that is at the crossroads of cell division and cell death. The goal of this study is to explore the expression features of prognostic immunohistochemical markers Ki-67, p53, β-catenin, AMACR (p503s), HER2-new in carcinomas of unknown primary of the colorectal phenotype compared with primary tumours of the colon, to improve diagnostic algorithms. Materials and methods. A study of biopsy material taken from 37 patients aged 28 to 81 years (mean 58.46 ± 12.28; median 58), group 1, with metastases without primary localization was carried out; the immunohistochemical investigation revealed adenocarcinomas of the colorectal phenotype CK20 + / CDX2 + / CK7; the investigation of postoperative material in 41 patients aged 27 to 76 years (mean 60.56 ± 12.81; median 64), group 2, revealed primary colon tumour. Results. Positive focal expression of p53 was found in the colorectal cancers of the proximal sections (located to the right), it is they that more often have microsatellite instability, compared to distal carcinomas. Amplification of the Her-2-new gene (expression at the level of 2+ and 3+) was found in 35% (13 of 37) of metastasis of colorectal cancers, and in almost 15% (6 of 41) of primary colon adenocarcinomas that suggests the appropriateness in applying targeted therapy.Conclusions. Nuclear translocation of β-catenin, positive “focal” expression of p53 and amplification of the Her-2-new gene are statistically significantly more common in colorectal phenotype metastases compared with primary colon adenocarcinomas (all р> 0.05).

Biomarkers predictive for pathologic response to neoadjuvant docetaxel/cyclophosphamide chemotherapy in primary breast cancer.

2013 ◽  
Vol 31 (26_suppl) ◽  
pp. 42-42
Author(s):  
Kazuhiro Shimada
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Statistical Significance ◽  
Complete Response ◽  
Pathological Response ◽  
Ki 67 ◽  
Immunohistochemical Markers ◽  
Oncology Research ◽  
Her 2 ◽  
Β Tubulin

42 Background: Since docetaxel /cyclophosphamide chemotherapy (TC) has proven to be superior to anthracycline/cyclophosphamide (AC) in U.S. Oncology Research Trial 9735, TC has been widely used for treating patients with breast cancer. However, taxane-specific adverse events like neuralgia and edema can’t be ignored. Thus, we performed neoadjuvant study with TC to clarify biological markers of this regimen. Methods: 79 patients with invasive breast cancer received TC (docetaxel 75 mg/m2, cyclophosphamide 600 mg/m2, q3w for 4 courses) at the neoadjuvant setting and underwent surgical treatment. Before treatment, the clinic-pathological and immunohistochemical markers (ER, PgR, HER-2, Ki-67, p53, topoisomerase IIα, ClassIII β tubulin, CK5/6, EGFR) were examined with core-needle biopsy specimens. The correlation between the pathological response and expressions of markers was investigated. Results: 33 patients (41.8%) achieved quasi-pathological complete response (QpCR). Univeriate analysis revealed that ER (p < 0.001), PgR (p = 0.007), Ki-67 (p = 0.022) and classIII β tubulin (p = 0.032) were associated with QpCR. Only ER (p = 0.050) and classIII β tubulin (p = 0.028) remained with a statistical significance at multivariate analysis. Subgroup analysis revealed that the negativity of CK5/6 and/or EGFR was correlated with QpCR in the triple negative subtype. Conclusions: ClassIII β tubulin had a specific predictive value for pathological response of TC in addition of ER, PgR and Ki-67. Sub-grouping is important for treating triple-negative breast cancer.

scholarly journals The Role of Immunohistochemical Markers for the Diagnosis and Prognosis of Adrenocortical Neoplasms

2021 ◽  
Vol 11 (3) ◽  
pp. 208
Author(s):  
Anna Angelousi ◽  
Georgios Kyriakopoulos ◽  
Fani Athanasouli ◽  
Anastasia Dimitriadi ◽  
Eva Kassi ◽  
...  
Keyword(s):  
Transcriptome Analysis ◽  
Cox Regression ◽  
P53 Protein ◽  
Immunohistochemical Analysis ◽  
Ki 67 ◽  
Diagnosis And Prognosis ◽  
Immunohistochemical Markers ◽  
Small Series ◽  
Morphological Criteria ◽  
Survival And Development

Adrenal cortical carcinoma (ACC) is a rare cancer with poor prognosis that needs to be distinguished from adrenocortical adenomas (ACAs). Although, the recently developed transcriptome analysis seems to be a reliable tool for the differential diagnosis of adrenocortical neoplasms, it is not widely available in clinical practice. We aim to evaluate histological and immunohistochemical markers for the distinction of ACCs from ACAs along with assessing their prognostic role. Clinical data were retrospectively analyzed from 37 patients; 24 archived, formalin-fixed, and paraffin-embedded ACC samples underwent histochemical analysis of reticulin and immunohistochemical analysis of p27, p53, Ki-67 markers and were compared with 13 ACA samples. Weiss and Helsinki scores were also considered. Kaplan−Meier and univariate Cox regression methods were implemented to identify prognostic effects. Altered reticulin pattern, Ki-67% labelling index and overexpression of p53 protein were found to be useful histopathological markers for distinguishing ACAs from ACCs. Among the studied markers, only pathological p53 nuclear protein expression was found to reach statistically significant association with poor survival and development of metastases, although in a small series of patients. In conclusion, altered reticulin pattern and p53/Ki-67 expression are useful markers for distinguishing ACCs from ACAs. Immunohistopathology alone cannot discriminate ACCs with different prognosis and it should be combined with morphological criteria and transcriptome analysis.

The Pattern of Proline, Glutamic Acid, and Leucine-Rich Protein 1 Expression in Chinese Women with Primary Breast Cancer

2014 ◽  
Vol 29 (1) ◽  
pp. e1-e7 ◽  
Author(s):  
Yanzhi Zhang ◽  
Peng Wang ◽  
Mumu Shi ◽  
Hironobu Sasano ◽  
Monica S.M. Chan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Glutamic Acid ◽  
Primary Breast Cancer ◽  
Chinese Women ◽  
Cancer Prognosis ◽  
Clinicopathological Parameters ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Her 2

Background Disparities of biomarkers’ expression in breast cancer across different races and ethnicities have been well documented. Proline, glutamic acid, and leucine-rich protein 1 (PELP1), a novel ER coregulator, has been considered as a promising biomarker of breast cancer prognosis; however, the pattern of PELP1 expression in Chinese women with breast cancer has never been investigated. This study aims to provide useful reference on possible racial or ethnic differences of PELP1 expression in breast cancer by exploring the pattern of PELP1 expression in Chinese women with primary breast cancer. Methods The expression of PELP1 in primary breast cancer samples from 130 Chinese female patients was detected by immunohistochemistry and correlated to other clinicopathological parameters; for comparison, the expression of PELP1 in 26 benign breast fibroadenomas was also examined. Results The overall value of the PELP1 H-score in breast cancer was significantly higher than that in breast fibroadenoma (p<0.001). In our breast cancer patients, the ER/HER-2-positive group had significantly higher PELP1 H-scores than their negative counterparts (p=0.003 for ER and p=0.022 for HER-2); the Ki-67-high group also showed significantly higher PELP1 H-scores than the Ki-67-low group (p=0.008). No significant association between PELP1 H-scores and other clinicopathological parameters was found. Finally, the PELP1 H-score in breast cancers of the luminal B subtype was significantly higher than that in the triple negative subtype (p=0.002). Conclusion Overexpression of PELP1 in Chinese women with primary breast cancer appears to be associated with biomarkers of poor outcome; these results are similar to other reports based on Western populations.

scholarly journals Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67

2018 ◽  
Vol Volume 11 ◽  
pp. 2269-2275 ◽  
Author(s):  
Junnan Xu ◽  
Xiangyu Guo ◽  
Mingxi Jing ◽  
Tao Sun
Keyword(s):  
Breast Cancer ◽  
Ki 67 ◽  
Tumor Mutation Burden ◽  
Mutation Burden ◽  
Her 2

Immunohistochemical expression of HER ‐ 2 and Ki ‐ 67 in granulosa cell tumor in bitches

2021 ◽  
Author(s):  
Ana Carina Heil da Silva Matos ◽  
Angélica Consalter ◽  
Bárbara Paula Santos Batista ◽  
Ana Beatriz Monteiro Fonseca ◽  
Ana Maria Reis Ferreira ◽  
...  
Keyword(s):  
Granulosa Cell ◽  
Granulosa Cell Tumor ◽  
Cell Tumor ◽  
Immunohistochemical Expression ◽  
Ki 67 ◽  
Her 2

Metastatic Basal Cell Carcinoma: Four Case Reports, Review of Literature, and Immunohistochemical Evaluation

2006 ◽  
Vol 130 (1) ◽  
pp. 45-51
Author(s):  
Diana N. Ionescu ◽  
Muammar Arida ◽  
Drazen M. Jukic
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Case Reports ◽  
Small Sample ◽  
Ki 67 ◽  
Immunohistochemical Markers ◽  
Metastatic Basal Cell Carcinoma ◽  
Metastatic Sites

Abstract Context.—Metastatic basal cell carcinoma (BCC) is relatively rare and is seldom considered a complication in the routine treatment and follow-up of patients with BCC. Although multiple studies have tried to distinguish aggressive from nonaggressive BCCs, to our knowledge, no consistent clinical, histopathologic, or immunohistochemical features have yet been reported. Objective.—To report 4 cases of metastatic BCCs and to evaluate these in addition to known nonmetastatic BCCs with specific immunostains in an attempt to find distinct morphologic or immunohistochemical patterns that could be helpful in identifying aggressive BCCs. Design.—We reviewed 4 cases of metastatic BCCs and recorded the clinical and morphologic findings. We then searched our archives for 14 cases of BCC that followed the usual nonaggressive course. We evaluated these 18 cases with immunohistochemical stains for Ki-67, p53, and bcl-2. Results.—In metastasizing BCC, Ki-67 staining was slightly higher in metastatic sites than in primary sites (average 63% and 51%, respectively). p53 was expressed in 3 of 4 primary sites and 2 of 4 metastatic sites. Bcl-2 was positive in both primary and metastatic sites in 3 of 4 cases. In the 14 cases of nonaggressive BCC, staining for Ki-67 averaged 38%, p53 was positive in 11 cases, and Bcl-2 staining was noted in 13 cases. Conclusions.—Overall, in the small sample that we evaluated, the immunohistochemical markers for Ki-67, p53, and Bcl-2 did not distinguish between metastatic and nonaggressive BCCs.

scholarly journals Nodular fasciitis on the zygomatic region: a rare presentation

2013 ◽  
Vol 88 (6 suppl 1) ◽  
pp. 89-92 ◽  
Author(s):  
Ilner de Souza e Souza ◽  
Mayra Carriijo Rochael ◽  
Rogério Estevam Farias ◽  
Roberto Bezerra Vieira ◽  
Janaina Silva Tirapelle Vieira ◽  
...  
Keyword(s):  
Benign Tumor ◽  
Histopathological Examination ◽  
Excisional Biopsy ◽  
Nodular Fasciitis ◽  
Rare Presentation ◽  
Ki 67 ◽  
Immunohistochemical Markers ◽  
The Face ◽  
Rare Location ◽  
High Cellularity

Nodular fasciitis is a benign tumor, resulting from reactive proliferation composed of fibroblastic/myofibroblastic cells. Due to its rapid growth and high cellularity it may be mistaken for sarcoma. Despite the possibility of spontaneous regression, excision is the treatment of choice. A 24-year-old female patient presented with a nodule on the zygomatic region with 3 months of evolution. Excisional biopsy was performed. Histopathological examination associated with immunohistochemical markers HHF35, AML and Ki-67 allowed diagnostic confirmation. The main relevance of the case presented is its rare location, suggesting its inclusion among the differential diagnoses of tumor lesions on the face.

Sign in / Sign up

Export Citation Format

Share Document